Literature DB >> 20075420

The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages.

Margarita de la Llera-Moya1, Denise Drazul-Schrader, Bela F Asztalos, Marina Cuchel, Daniel J Rader, George H Rothblat.   

Abstract

OBJECTIVE: We measured efflux from macrophages to apolipoprotein B-depleted serum from 263 specimens and found instances in which serum having similar high-density lipoprotein cholesterol (HDL-C) differed in their efflux capacity. Thus, we wanted to elucidate why efflux capacity could be independent of total HDL-C or apolipoprotein A-I (apoA-I). METHODS AND
RESULTS: To understand why sera with similar HDL-C or apoA-I could differ in total efflux capacity, we assessed their ability to promote efflux via the pathways expressed in cAMP-treated J774 macrophages. Briefly, macrophages were preincubated with probucol to block ABCA1, with BLT-1 to block SR-BI, and with both inhibitors to measure residual efflux. ABCG1 efflux was measured with transfected BHK-1 cells. We used apolipoprotein B-depleted serum from specimens with similar HDL-C values at the 25(th) and 75(th) percentiles. Specimens in each group were classified as having high or low efflux based on total efflux being above or below the group average. We found that independently of HDL-C, sera with higher efflux capacity had a significant increase in ABCA1-mediated efflux, which was significantly correlated to the concentration of pre beta-1 HDL. The same result was obtained when these sera were similarly analyzed based on similar apoA-I.
CONCLUSIONS: Sera with similar HDL-C or apoA-I differ in their ability to promote macrophage efflux because of differences in the concentration of pre beta-1 HDL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20075420      PMCID: PMC2866499          DOI: 10.1161/ATVBAHA.109.199158

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  32 in total

1.  Genetics of increased HDL cholesterol levels: insights into the relationship between HDL metabolism and atherosclerosis.

Authors:  Marina Cuchel; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-10-01       Impact factor: 8.311

2.  Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity.

Authors:  K Hirano; S Yamashita; N Nakajima; T Arai; T Maruyama; Y Yoshida; M Ishigami; N Sakai; K Kameda-Takemura; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-06       Impact factor: 8.311

3.  Oxidative tyrosylation of high density lipoprotein by peroxidase enhances cholesterol removal from cultured fibroblasts and macrophage foam cells.

Authors:  G A Francis; A J Mendez; E L Bierman; J W Heinecke
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

4.  In vitro oxidised HDL is recognized by the scavenger receptor of macrophages: implications for its protective role in vivo.

Authors:  A E La Ville; R Sola; J Balanya; P R Turner; L Masana
Journal:  Atherosclerosis       Date:  1994-02       Impact factor: 5.162

5.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

Authors:  T Gordon; W P Castelli; M C Hjortland; W B Kannel; T R Dawber
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

6.  Nitrosylated high density lipoprotein is recognized by a scavenger receptor in rat liver.

Authors:  M F Kleinherenbrink-Stins; D Schouten; J van der Boom; A Brouwer; D L Knook; T J van Berkel
Journal:  J Lipid Res       Date:  1989-04       Impact factor: 5.922

7.  Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein.

Authors:  Elda Favari; Miriam Lee; Laura Calabresi; Guido Franceschini; Francesca Zimetti; Franco Bernini; Petri T Kovanen
Journal:  J Biol Chem       Date:  2003-12-29       Impact factor: 5.157

Review 8.  Transgenic mouse models of lipoprotein metabolism and atherosclerosis.

Authors:  J L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

9.  High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.

Authors:  D J Gordon; J L Probstfield; R J Garrison; J D Neaton; W P Castelli; J D Knoke; D R Jacobs; S Bangdiwala; H A Tyroler
Journal:  Circulation       Date:  1989-01       Impact factor: 29.690

10.  Biological variability in concentrations of serum lipids: sources of variation among results from published studies and composite predicted values.

Authors:  S J Smith; G R Cooper; G L Myers; E J Sampson
Journal:  Clin Chem       Date:  1993-06       Impact factor: 8.327

View more
  175 in total

1.  The lipid transfer properties of CETP define the concentration and composition of plasma lipoproteins.

Authors:  Richard E Morton; Yan Liu
Journal:  J Lipid Res       Date:  2020-06-26       Impact factor: 5.922

2.  Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects.

Authors:  Urbain Tchoua; Corina Rosales; Daming Tang; Baiba K Gillard; Ashley Vaughan; Hu Yu Lin; Harry S Courtney; Henry J Pownall
Journal:  Lipids       Date:  2010-10-24       Impact factor: 1.880

3.  A sensitive assay for ABCA1-mediated cholesterol efflux using BODIPY-cholesterol.

Authors:  Sandhya Sankaranarayanan; Ginny Kellner-Weibel; Margarita de la Llera-Moya; Michael C Phillips; Bela F Asztalos; Robert Bittman; George H Rothblat
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

Review 4.  Therapeutic strategies to deplete macrophages in atherosclerotic plaques.

Authors:  Inge De Meyer; Wim Martinet; Guido R Y De Meyer
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

5.  Impact of self-association on function of apolipoprotein A-I.

Authors:  Shobini Jayaraman; Sumiko Abe-Dohmae; Shinji Yokoyama; Giorgio Cavigiolio
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

6.  Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein.

Authors:  Jonathan D Smith
Journal:  J Clin Lipidol       Date:  2010 Sep-Oct       Impact factor: 4.766

7.  HDL-apolipoprotein A-I exchange is independently associated with cholesterol efflux capacity.

Authors:  Mark S Borja; Kit F Ng; Angela Irwin; Jaekyoung Hong; Xing Wu; Daniel Isquith; Xue-Qiao Zhao; Bryan Prazen; Virginia Gildengorin; Michael N Oda; Tomáš Vaisar
Journal:  J Lipid Res       Date:  2015-08-07       Impact factor: 5.922

8.  Cholesterol Efflux Capacity and Subclasses of HDL Particles in Healthy Women Transitioning Through Menopause.

Authors:  Samar R El Khoudary; Patrick M Hutchins; Karen A Matthews; Maria M Brooks; Trevor J Orchard; Graziella E Ronsein; Jay W Heinecke
Journal:  J Clin Endocrinol Metab       Date:  2016-07-11       Impact factor: 5.958

Review 9.  Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL.

Authors:  Patrick M Hutchins; Jay W Heinecke
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

10.  Inhibition of ABCA1 protein degradation promotes HDL cholesterol efflux capacity and RCT and reduces atherosclerosis in mice.

Authors:  LinZhang Huang; BaoYan Fan; Ang Ma; Philip W Shaul; HaiBo Zhu
Journal:  J Lipid Res       Date:  2015-03-11       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.